Acute Kidney Injury — Part 2: Etiology, Diagnostic Workup & Prevention

1. Etiology of AKI in Critical Care

1.1 Classification by Anatomic Site

AKI is traditionally classified according to the anatomic site of the predominant pathology. In critically ill patients, multiple mechanisms frequently coexist (e.g., sepsis-induced hemodynamic compromise superimposed on nephrotoxin exposure), and the traditional “pre-renal / intrinsic / post-renal” framework — while clinically useful — represents a simplification of complex, overlapping pathophysiology.^{1 2}

1.2 Pre-Renal AKI (Functional / Hemodynamic)

Pre-renal AKI results from reduced renal perfusion without structural parenchymal damage. It is the most common cause of AKI in hospitalized patients (40-55% of cases). By definition, pre-renal AKI is rapidly reversible with restoration of adequate perfusion, though prolonged or severe hypoperfusion leads to ischemic tubular injury (ATN).¹

1.3 Intrinsic Renal AKI

Intrinsic AKI involves structural damage to one or more components of the renal parenchyma. Acute tubular necrosis (ATN) is by far the most common form in the ICU setting.^{1 2}

1.3.1 Acute Tubular Necrosis (ATN)

1.3.2 Acute Interstitial Nephritis (AIN)

AIN accounts for 5-10% of AKI in the ICU. It is an immune-mediated inflammation of the renal interstitium, most commonly drug-induced.³

Classic triad (present in < 30% of cases): Fever, rash, eosinophilia

Diagnostic clue: Sterile pyuria, white blood cell casts, eosinophiluria (> 1% by Hansel stain — sensitivity only 40-60%)

1.3.3 Glomerulonephritis (GN)

Rapidly progressive glomerulonephritis (RPGN) is uncommon but important to recognize early, as it may require immunosuppressive therapy and/or plasmapheresis.¹

1.3.4 Vascular Causes

1.4 Post-Renal AKI (Obstructive)

Post-renal AKI accounts for 5-10% of AKI in hospitalized patients but is critical to identify because it is often rapidly reversible with relief of obstruction. Bilateral obstruction (or unilateral in a solitary kidney) is required to cause significant AKI.¹

2. Diagnostic Workup

2.1 Initial Assessment Algorithm

For every patient meeting AKI criteria, the following stepwise evaluation should be performed:^{1 2}

1. Assess volume status — clinical examination (JVP, peripheral edema, lung crackles, skin turgor), point-of-care ultrasound (IVC collapsibility, lung B-lines), hemodynamic monitoring
2. Review medication list — identify and discontinue nephrotoxins when possible
3. Rule out obstruction — bladder scan / Foley catheter assessment; renal ultrasound if obstruction suspected
4. Obtain urinalysis and microscopy — essential for distinguishing pre-renal from intrinsic causes
5. Calculate fractional excretion of sodium (FENa) and/or urea (FEUrea) — if pre-renal vs. ATN distinction is unclear
6. Targeted serologic/immunologic workup — if glomerulonephritis or vasculitis is suspected (ANCA, anti-GBM, complement, ANA, anti-dsDNA)
7. Renal biopsy — if cause remains unclear and diagnosis will change management

2.2 Urinalysis and Urine Microscopy

Urine microscopy is the “renal biopsy of the ICU” — a simple, inexpensive test that provides critical diagnostic information when performed and interpreted correctly.⁴

2.3 Fractional Excretion of Sodium (FENa) and Urea (FEUrea)

These calculated indices help differentiate pre-renal AKI (avid sodium and urea reabsorption by intact tubules) from ATN (impaired tubular reabsorption).^{1 5}

FENa = (Urine Na × Plasma Cr) / (Plasma Na × Urine Cr) × 100

FEUrea = (Urine Urea × Plasma Cr) / (Plasma Urea × Urine Cr) × 100

Clinical Pearl: The “intermediate zone” (FENa 1-2%, FEUrea 35-50%) is common in ICU patients and does not reliably distinguish between pre-renal and intrinsic AKI. In these cases, the clinical trajectory, response to volume challenge, and urinalysis findings are more informative than the calculated indices.

2.4 Renal Imaging

3. Prevention of AKI

3.1 Volume Optimization

Optimizing intravascular volume is the cornerstone of AKI prevention. Both hypovolemia (inadequate renal perfusion) and hypervolemia (venous congestion, increased renal interstitial pressure) contribute to kidney injury.^{1 6}

Key Principles:

• Avoid prolonged hypovolemia: Early, goal-directed resuscitation in sepsis, trauma, and perioperative settings reduces AKI incidence
• Avoid fluid overload: Cumulative fluid balance > 10% of body weight is independently associated with increased AKI severity, need for RRT, and mortality⁷
• Fluid type matters: Balanced crystalloids (Ringer’s lactate, Plasmalyte) are preferred over 0.9% saline for large-volume resuscitation; the SMART trial demonstrated reduced rates of the composite outcome of death, new RRT, or persistent renal dysfunction with balanced crystalloids vs. saline (14.3% vs. 15.4%, p = 0.04)⁸
• Avoid hydroxyethyl starch (HES): HES is associated with increased AKI and RRT requirement in critically ill patients and is contraindicated (VISEP, 6S, CHEST trials)^{9 10}

3.2 Hemodynamic Targets

• Mean arterial pressure (MAP) ≥ 65 mmHg is the standard target for critically ill patients⁶
• Higher MAP targets (75-80 mmHg) may benefit patients with chronic hypertension in terms of AKI prevention (SEPSISPAM trial: reduced RRT requirement in the chronic hypertension subgroup with MAP 80-85 vs. 65-70, though no overall mortality benefit)¹¹
• Avoid vasopressors in hypovolemia: Vasopressors should not be used as a substitute for volume resuscitation but are appropriate for refractory hypotension after adequate volume replacement

3.3 Nephrotoxin Avoidance and Stewardship

Exposure to nephrotoxic medications is a modifiable risk factor for AKI. A structured nephrotoxin stewardship program can reduce AKI incidence by 20-40%.¹²

Common Nephrotoxins in the ICU

3.4 Contrast-Associated AKI — Evolving Evidence

The risk of contrast-associated AKI (CA-AKI) has been a subject of significant controversy and evolving understanding:^{13 14}

Historical perspective: Contrast-induced nephropathy was historically considered a common and serious complication of iodinated contrast administration, with early studies reporting incidence rates of 10-30% in high-risk populations.

Current evidence challenges this view:

• Large propensity-matched observational studies have demonstrated that the incidence of AKI after contrast exposure is similar to the incidence of AKI in matched patients undergoing similar procedures without contrast (suggesting that much of what was attributed to contrast was actually due to the underlying clinical context)¹³
• The risk of CA-AKI appears to be clinically significant primarily in patients with eGFR < 30 mL/min/1.73 m² undergoing intra-arterial contrast administration
• For intravenous contrast (CT scans), the true attributable risk of AKI is likely very low, even in patients with moderate CKD (eGFR 30-44)¹⁴
• Fear of contrast should never delay critical diagnostic imaging in acutely ill patients

Current recommendations for contrast use in at-risk patients:

Key Point: N-acetylcysteine (NAC) has not been shown to prevent CA-AKI in the large, well-designed PRESERVE trial and should not be used for this purpose.¹⁵

3.5 Glycemic Control

• Target blood glucose 110-180 mg/dL in critically ill patients
• Avoid tight glycemic control (target 80-110 mg/dL), which increases hypoglycemia risk without renal benefit (NICE-SUGAR trial)¹⁶
• Hyperglycemia > 180 mg/dL is associated with increased AKI risk and should be treated with insulin infusion

3.6 Drug Dose Adjustment in AKI

Drug dosing must be adjusted for reduced renal clearance in AKI. The following table provides guidance for commonly used ICU medications:^{1 17}

4. Pathophysiology of AKI — Key Mechanisms

4.1 Ischemic ATN

The pathophysiology of ischemic ATN involves a sequence of hemodynamic, tubular, and inflammatory events:²

1. Initiation phase: Reduced renal blood flow → ATP depletion in tubular epithelial cells (particularly in the metabolically active S3 segment of the proximal tubule and the medullary thick ascending limb, which operate at the margin of oxygen supply-demand balance)
2. Extension phase: Continued hypoxia, inflammation (leukocyte adhesion, cytokine release), microvascular congestion, endothelial injury → propagation of injury beyond the initial insult
3. Maintenance phase: GFR remains reduced despite restoration of renal blood flow; tubular cell necrosis and apoptosis, back-leak of filtrate through denuded basement membrane, tubular obstruction by cellular debris; typically lasts 1-2 weeks
4. Recovery phase: Tubular cell regeneration and re-differentiation; resolution of inflammation; gradual restoration of GFR; may be complete or incomplete

4.2 Nephrotoxic ATN

Nephrotoxic ATN involves direct cellular injury to tubular epithelial cells through various mechanisms depending on the toxin:²

• Aminoglycosides: Proximal tubular uptake via megalin/cubilin receptors → lysosomal phospholipidosis → oxidative stress → cell death (typically non-oliguric; onset after 5-7 days of therapy)
• Cisplatin: Proximal and distal tubular uptake → DNA damage, mitochondrial dysfunction, oxidative stress → apoptosis and necrosis
• Myoglobin (rhabdomyolysis): Tubular obstruction by myoglobin casts, direct oxidative injury via ferryl myoglobin, renal vasoconstriction via nitric oxide scavenging
• Contrast agents: Medullary ischemia (vasoconstriction), direct tubular cytotoxicity, tubular obstruction by Tamm-Horsfall protein precipitates

4.3 Sepsis-Associated AKI — Distinct Pathophysiology

Sepsis-associated AKI has a fundamentally different pathophysiology from classical ischemic ATN (see Part 5 for detailed discussion). Key distinctions include:¹⁸

• Renal blood flow is often normal or increased (not decreased) in sepsis
• Tubular necrosis is often minimal on histopathology, despite severe functional impairment
• Mechanisms involve microvascular dysfunction, mitochondrial “hibernation,” toll-like receptor activation, and inflammatory cell infiltration
• This has implications for management: aggressive volume resuscitation targeting increased renal blood flow may not be beneficial and may cause harm through fluid overload

5. Goal-Directed Hemodynamic Therapy for AKI Prevention

5.1 Perioperative Settings

Goal-directed hemodynamic therapy (GDHT) using cardiac output monitors, dynamic preload indicators, or stroke volume optimization has been shown to reduce AKI incidence in high-risk surgical patients:⁶

• Principles: Optimize stroke volume and cardiac output to ensure adequate oxygen delivery (DO2) to end organs including the kidneys
• Dynamic parameters preferred over static: Pulse pressure variation (PPV), stroke volume variation (SVV), and passive leg raise (PLR) are preferred over central venous pressure (CVP) for guiding fluid administration
• CVP and AKI: Elevated CVP (> 12-15 mmHg) is associated with increased AKI risk through renal venous congestion, independent of cardiac output; therefore, both arterial underfilling and venous congestion must be addressed¹⁹

5.2 Renal Perfusion Pressure

Renal perfusion pressure (RPP) can be conceptualized as:

RPP = MAP - CVP (or MAP - intra-abdominal pressure, whichever back-pressure is higher)

This framework highlights that AKI can result from:

• Low MAP (underperfusion)
• High CVP (venous congestion)
• High intra-abdominal pressure (abdominal compartment syndrome)
• Any combination of these

References